山西将全面执行第十一批国家组织55种药品集采中选结果

Core Viewpoint - The implementation of the 11th batch of national organized drug centralized procurement will significantly reduce the financial burden on patients by lowering the prices of essential medications across various therapeutic areas [1][2] Group 1: Drug Procurement Details - A total of 55 types of drugs and 453 products have been selected for centralized procurement, covering common medications for infections, allergies, tumors, blood sugar, blood pressure, blood lipids, and pain relief [1] - The procurement includes treatments for both common chronic diseases and some rare diseases, exemplified by the reduction in monthly costs for idiopathic pulmonary fibrosis treatment from over 7000 yuan to several hundred yuan [1] Group 2: Procurement Rules Optimization - The procurement rules have been optimized to ensure clinical stability, quality assurance, prevention of internal competition, and anti-collusion measures [2] - Medical institutions can report quantities by brand, allowing them to use selected drugs without changing brands, thus matching clinical needs with lower-priced options [2] - New quality standards have been introduced, requiring at least two years of production experience and compliance with GMP for bidders [2] - Innovative mechanisms such as "anchor pricing" and "revival of non-selected drugs" have been implemented to stabilize pricing and prevent collusion among companies [2] - The province will continue to enhance the quality and accessibility of procured drugs, aiming to alleviate the medication burden on the public [2]